Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Director George L. Sing sold 3,000 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $608.91, for a total transaction of $1,826,730.00. Following the completion of the transaction, the director now owns 115,415 shares of the company’s stock, valued at $70,277,347.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of NASDAQ REGN opened at $623.65 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.49 and a current ratio of 4.21. Regeneron Pharmaceuticals Inc has a fifty-two week low of $271.37 and a fifty-two week high of $646.33. The firm has a market capitalization of $67.71 billion, a PE ratio of 31.34, a price-to-earnings-growth ratio of 1.93 and a beta of 0.57. The stock’s 50-day simple moving average is $593.41 and its 200-day simple moving average is $476.16.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share for the quarter, topping the consensus estimate of $6.13 by $0.47. Regeneron Pharmaceuticals had a return on equity of 24.94% and a net margin of 28.56%. The business had revenue of $1.83 billion for the quarter, compared to analyst estimates of $1.81 billion. During the same quarter last year, the company earned $4.45 EPS. The business’s quarterly revenue was up 6.8% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals Inc will post 23.48 earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on REGN shares. Barclays boosted their price target on Regeneron Pharmaceuticals from $530.00 to $615.00 in a research note on Thursday, May 28th. BidaskClub lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, June 10th. JPMorgan Chase & Co. boosted their price target on Regeneron Pharmaceuticals from $375.00 to $429.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Benchmark started coverage on Regeneron Pharmaceuticals in a research report on Sunday, April 19th. They issued a “hold” rating on the stock. Finally, ValuEngine upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, March 9th. Fifteen equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $548.86.
Several hedge funds and other institutional investors have recently modified their holdings of REGN. OmniStar Financial Group Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $28,000. CX Institutional increased its position in Regeneron Pharmaceuticals by 144.0% during the first quarter. CX Institutional now owns 61 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 36 shares during the period. Parkside Financial Bank & Trust increased its position in Regeneron Pharmaceuticals by 44.2% during the first quarter. Parkside Financial Bank & Trust now owns 62 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 19 shares during the period. Globeflex Capital L P acquired a new position in Regeneron Pharmaceuticals during the first quarter worth approximately $31,000. Finally, Americana Partners LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth approximately $39,000. 68.04% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: Preferred Stock
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.